
Terressa M. Boykin
Examiner (ID: 5881, Phone: (571)272-1069 , Office: P/1765 )
| Most Active Art Unit | 1765 |
| Art Unit(s) | 1764, 1207, 1711, 1796, 1503, 1765 |
| Total Applications | 4786 |
| Issued Applications | 4211 |
| Pending Applications | 203 |
| Abandoned Applications | 406 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17185558
[patent_doc_number] => 20210332443
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-28
[patent_title] => Molecular Marker and Application Method for Assisted Breeding of Fine-wool Sheep
[patent_app_type] => utility
[patent_app_number] => 17/009867
[patent_app_country] => US
[patent_app_date] => 2020-09-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4087
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17009867
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/009867 | Molecular Marker and Application Method for Assisted Breeding of Fine-wool Sheep | Sep 1, 2020 | Abandoned |
Array
(
[id] => 16621884
[patent_doc_number] => 20210040537
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-11
[patent_title] => SELECTIVE ENRICHMENT
[patent_app_type] => utility
[patent_app_number] => 16/987601
[patent_app_country] => US
[patent_app_date] => 2020-08-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10693
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 78
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16987601
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/987601 | SELECTIVE ENRICHMENT | Aug 6, 2020 | Abandoned |
Array
(
[id] => 17867510
[patent_doc_number] => 20220290246
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-15
[patent_title] => SINGLE NUCLEOTIDE POLYMORPHISMS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/632950
[patent_app_country] => US
[patent_app_date] => 2020-08-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16418
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -30
[patent_words_short_claim] => 68
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17632950
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/632950 | SINGLE NUCLEOTIDE POLYMORPHISMS AND USES THEREOF | Aug 6, 2020 | Abandoned |
Array
(
[id] => 16420506
[patent_doc_number] => 20200345704
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-05
[patent_title] => COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS
[patent_app_type] => utility
[patent_app_number] => 16/934724
[patent_app_country] => US
[patent_app_date] => 2020-07-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17135
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16934724
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/934724 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | Jul 20, 2020 | Abandoned |
Array
(
[id] => 16450904
[patent_doc_number] => 20200360330
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-19
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASE
[patent_app_type] => utility
[patent_app_number] => 16/923311
[patent_app_country] => US
[patent_app_date] => 2020-07-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16062
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 3
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16923311
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/923311 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASE | Jul 7, 2020 | Abandoned |
Array
(
[id] => 17830551
[patent_doc_number] => 20220267855
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-25
[patent_title] => A Method for Predicting Prognosis of Cancer and the Composition Thereof
[patent_app_type] => utility
[patent_app_number] => 17/608422
[patent_app_country] => US
[patent_app_date] => 2020-04-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12126
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17608422
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/608422 | A Method for Predicting Prognosis of Cancer and the Composition Thereof | Apr 27, 2020 | Pending |
Array
(
[id] => 16511507
[patent_doc_number] => 20200390764
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-17
[patent_title] => PHARMACEUTICAL FORMULATIONS, PROCESSES FOR PREPARATION, AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 16/859111
[patent_app_country] => US
[patent_app_date] => 2020-04-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17121
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16859111
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/859111 | PHARMACEUTICAL FORMULATIONS, PROCESSES FOR PREPARATION, AND METHODS OF USE | Apr 26, 2020 | Abandoned |
Array
(
[id] => 17673132
[patent_doc_number] => 20220186299
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-16
[patent_title] => METHOD FOR DIAGNOSING CELIAC DISEASE BASED ON THE LEVEL OF EXPRESSION OF THE UBE2L3 GENE
[patent_app_type] => utility
[patent_app_number] => 17/439446
[patent_app_country] => US
[patent_app_date] => 2020-03-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8448
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17439446
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/439446 | METHOD FOR DIAGNOSING CELIAC DISEASE BASED ON THE LEVEL OF EXPRESSION OF THE UBE2L3 GENE | Mar 12, 2020 | Pending |
Array
(
[id] => 16328815
[patent_doc_number] => 20200299781
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-24
[patent_title] => Prediction of Likelihood of Cancer Recurrence
[patent_app_type] => utility
[patent_app_number] => 16/807769
[patent_app_country] => US
[patent_app_date] => 2020-03-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11100
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16807769
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/807769 | Prediction of Likelihood of Cancer Recurrence | Mar 2, 2020 | Abandoned |
Array
(
[id] => 16009017
[patent_doc_number] => 20200179351
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-11
[patent_title] => TREATMENT OF DEPRESSIVE DISORDERS
[patent_app_type] => utility
[patent_app_number] => 16/794354
[patent_app_country] => US
[patent_app_date] => 2020-02-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12151
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16794354
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/794354 | TREATMENT OF DEPRESSIVE DISORDERS | Feb 18, 2020 | Abandoned |
Array
(
[id] => 16236745
[patent_doc_number] => 20200253979
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-13
[patent_title] => THERAPEUTIC METHODS RELATING TO HSP90 INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 16/782508
[patent_app_country] => US
[patent_app_date] => 2020-02-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25047
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -40
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16782508
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/782508 | THERAPEUTIC METHODS RELATING TO HSP90 INHIBITORS | Feb 4, 2020 | Abandoned |
Array
(
[id] => 15765825
[patent_doc_number] => 20200113930
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-16
[patent_title] => Methods And Compositions For Bowel Cleansing Before A Medical Procedure
[patent_app_type] => utility
[patent_app_number] => 16/714473
[patent_app_country] => US
[patent_app_date] => 2019-12-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4367
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 96
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16714473
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/714473 | Methods And Compositions For Bowel Cleansing Before A Medical Procedure | Dec 12, 2019 | Abandoned |
Array
(
[id] => 17370406
[patent_doc_number] => 20220025458
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-27
[patent_title] => METHOD FOR PROVIDING AN IDENTIFIER FOR A PRODUCT
[patent_app_type] => utility
[patent_app_number] => 17/298471
[patent_app_country] => US
[patent_app_date] => 2019-11-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23423
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17298471
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/298471 | METHOD FOR PROVIDING AN IDENTIFIER FOR A PRODUCT | Nov 28, 2019 | Abandoned |
Array
(
[id] => 16374994
[patent_doc_number] => 20200323836
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-15
[patent_title] => SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES
[patent_app_type] => utility
[patent_app_number] => 16/687467
[patent_app_country] => US
[patent_app_date] => 2019-11-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14861
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16687467
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/687467 | SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES | Nov 17, 2019 | Abandoned |
Array
(
[id] => 17126175
[patent_doc_number] => 20210300943
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-30
[patent_title] => OGA INHIBITOR COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 17/253432
[patent_app_country] => US
[patent_app_date] => 2019-06-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 43614
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17253432
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/253432 | OGA INHIBITOR COMPOUNDS | Jun 19, 2019 | Abandoned |
Array
(
[id] => 15024157
[patent_doc_number] => 20190323083
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-24
[patent_title] => SYNCHRONIZED CELL CYCLE GENE EXPRESSION TEST FOR ALZHEIMER'S DISEASE AND RELATED THERAPEUTIC METHODS
[patent_app_type] => utility
[patent_app_number] => 16/434362
[patent_app_country] => US
[patent_app_date] => 2019-06-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13991
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16434362
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/434362 | SYNCHRONIZED CELL CYCLE GENE EXPRESSION TEST FOR ALZHEIMER'S DISEASE AND RELATED THERAPEUTIC METHODS | Jun 6, 2019 | Abandoned |
Array
(
[id] => 15898197
[patent_doc_number] => 20200148617
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-14
[patent_title] => GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR
[patent_app_type] => utility
[patent_app_number] => 16/402853
[patent_app_country] => US
[patent_app_date] => 2019-05-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 82520
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16402853
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/402853 | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | May 2, 2019 | Abandoned |
Array
(
[id] => 14926153
[patent_doc_number] => 20190298714
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-03
[patent_title] => USE OF LEVOCETIRIZINE AND MONTELUKAST TO TREAT RHINOSINUSITIS AND NASAL POLYPOSIS
[patent_app_type] => utility
[patent_app_number] => 16/382077
[patent_app_country] => US
[patent_app_date] => 2019-04-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11955
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16382077
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/382077 | USE OF LEVOCETIRIZINE AND MONTELUKAST TO TREAT RHINOSINUSITIS AND NASAL POLYPOSIS | Apr 10, 2019 | Abandoned |
Array
(
[id] => 14534437
[patent_doc_number] => 20190202840
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-07-04
[patent_title] => SALTS OF (S)-7-(1-(9H-PURIN-6-YLAMINO)ETHYL)-6-(3-FLUOROPHENYL)-3-METHYL-5H-THIAZOLO[3,2-A]PYRIMIDIN-5-ONE
[patent_app_type] => utility
[patent_app_number] => 16/295435
[patent_app_country] => US
[patent_app_date] => 2019-03-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14553
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16295435
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/295435 | SALTS OF (S)-7-(1-(9H-PURIN-6-YLAMINO)ETHYL)-6-(3-FLUOROPHENYL)-3-METHYL-5H-THIAZOLO[3,2-A]PYRIMIDIN-5-ONE | Mar 6, 2019 | Abandoned |
Array
(
[id] => 16506533
[patent_doc_number] => 20200385789
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-10
[patent_title] => METHODS OF ASSESSING TELOMERES
[patent_app_type] => utility
[patent_app_number] => 16/643398
[patent_app_country] => US
[patent_app_date] => 2018-08-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17882
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -49
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16643398
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/643398 | METHODS OF ASSESSING TELOMERES | Aug 30, 2018 | Abandoned |